United States: No X-Ray Vision At The FTC: Court Hands Agency A Rare Defeat In The Steris/Synergy Merger

In FTC v. Steris, the FTC was handed a rare litigation defeat. The case was notable because it involved a merger between companies who were not current competitors. The FTC alleged that without the merger, Synergy would have entered the US sterilization market with a disruptive new technology that would have undermined the current duopoly and benefited customers. The court found little in the evidence to support the FTC's theory. To be sure, there will be some soul-searching at the FTC as to how the Court could find the weight of the evidence so strongly on the side of the merging parties. However, because the case was decided on the single factual question of whether Synergy would have entered the U.S. market independently, the case has little precedential value and is unlikely to significantly alter the FTC's general approach to mergers involving potential competitors.

Introduction

In FTC v. Steris, District Court Judge Polster handed a rare defeat to the FTC. The case was notable because it involved a merger between companies who were not current competitors. The FTC alleged that without the merger, Synergy would have entered the US sterilization market with a disruptive new technology that would have undermined the current duopoly and benefited customers. The case was therefore about a merger that eliminated only future or actual potential competition. Although potential competition concerns are not novel for the FTC, this case was closely watched because it promised to be the first judicial treatment of potential competition in many years. Unfortunately for antitrust lawyers, the decision is something of a missed opportunity: the Court did not examine the validity or scope of the potential competition doctrine. Instead, the case was decided on the single question of whether the evidence showed that Synergy would have entered the US market within a reasonable period. On this key threshold question—which the Court rightly identified as the decisive issue—the Court found the evidence unequivocally supported the merging parties. The Court found that—given the enormous technical, financial, and business hurdles to entry and the notable lack of any customer commitments to an unproven technology—the FTC could not show that Synergy probably would have entered the market but for the merger.

Background

On October 13, 2014, the parties announced Ohio-based Steris' proposed acquisition of UK-based Synergy, for approximately $1.9 billion, which would combine the second and third largest medical sterilization companies in the world. Steris and Synergy claimed that the transaction would combine their geographically complementary businesses. Steris was one of only two US providers of contract gamma radiation sterilization services. Gamma radiation sterilization is the most effective and economical option for many healthcare products that are required to be sterilized by the FDA. Gamma radiation sterilization in the US is essentially a duopoly, with the top two providers accounting for about 85% of the market. By contrast, Synergy had only a small sterilization presence in the United States, with no US gamma offering. Although Synergy did not currently compete with Steris, the FTC focused on Synergy's plans to enter the United States with new x-ray based sterilization technology. After an intensive Second Request investigation, the FTC filed a complaint in the Northern District of Ohio seeking injunctive relief against the proposed transaction, alleging that Synergy would have become a significant competitor to Steris in contract sterilization services and that Synergy abandoned its entry plans because of the merger. The FTC also issued an Administrative Complaint challenging the merger.

Key Factors in the Decision

The court requested briefing and held three days of hearings in which it listened to testimony from Synergy executives as well as representatives from potential customers J&J and Zimmer. The Court found no support for the FTC's contention that Synergy abandoned its entry plans because of the merger. Instead, the Court decided that Synergy abandoned the project for legitimate business reasons unrelated to the merger. In the court's view, a lack of customer commitment, the inability to lower capital costs and other problems "plagued the development of x-ray sterilization" and justified Synergy's decision to terminate the entry project. While the FTC argued that Synergy's ordinary course documents established that the company was "poised" to enter the US with disruptive technology and an expectation of winning the incumbents' highest-valued customers, Synergy maintained that the documents painted a bleak outlook for the project, an assessment that the court accepted. Synergy's business models showed the entry strategy would fail every one of Synergy's internal financial metrics. In addition, while Synergy's Board had endorsed the idea, a formal business plan for US entry had never been presented to or approved by the Board. The court focused heavily on the risk profile of Synergy's entry strategy, noting that the investment was a "bet the farm" proposition that would consume Synergy's entire annual discretionary budget.

Critically, any investment decision would also need to be backed by long-term commitments from customers. However, despite intense marketing and sales efforts, Synergy was unable to obtain a single customer commitment to x-ray technology. Because of the high costs in obtaining FDA-validation for x-ray sterilization, the court observed that there was no financial incentive for customers to switch from existing technology to x-ray based services. The FTC asserted that it was the proposed merger and the FTC's own investigation into the deal that prompted Synergy to abandon its x-ray plans. Once again, the court disagreed, observing that Synergy did not terminate its plans until February 24, 2015, four months following the deal's announcement. Judge Polster noted that, "the timing of the decision to pull the plug on the US x-ray project may actually be the best evidence that it was done for legitimate business reasons, as opposed to anti-competitive ones. If the merger with Steris was going to prevent Synergy from entering the US market, Synergy would have stopped working on the US x-ray project as soon as the merger was announced in mid-October 2014."

 In the court's assessment, the x-ray entry strategy faced insurmountable hurdles that justified the decision to abandon the project entirely. Accordingly, the FTC could not carry its burden of establishing that Synergy would have entered the US market within a reasonable period but for the merger.

Conclusion

While the FTC may decide to appeal and/or may continue its in-house administrative proceedings against the merger, the prospects of a successful appeal are low. The decision was based on three days of oral hearings involving numerous determinations of witness credibility and a careful review of documentary evidence. To the extent it comes before the Court of Appeals, it will pay special deference to the District Court's account of the evidence and, if plausible, will not overturn the trial court even if it might have weighed the evidence differently.

Although there will be some soul-searching at the FTC as to how the Court could find the weight of the evidence so strongly on the side of the merging parties, the case is likely to have little impact on the FTC's general approach in potential competition cases. Indeed, if there is any solace for the FTC in this matter, it is that the Court was at least prepared to assume the validity of the actual potential competition doctrine rather than narrowly interpreting it in a way that may have constrained the Government's ability to challenge transactions on similar grounds in the future.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions